Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity

Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial

(2015) Kumiko Tanaka et al.   CLINICAL DRUG INVESTIGATION

Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

(2015) Kumiko Tanaka et al.   ENDOCRINE JOURNAL

GLP-1 based therapeutics: simultaneously combating T2DM and obesity

(2015) Kristy M. Heppner et al.   Frontiers in Neuroscience

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes

(2015) Benjamin Udoka Nwosu et al.   PLoS One

Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial

(2014) Bettina Nowotny et al.   DIABETOLOGIA

A new ester of fatty acid from a methanol extract of the whole plant ofAmaranthus spinosusand itsα-glucosidase inhibitory activity

(2014) Arijit Mondal et al.   PHARMACEUTICAL BIOLOGY

Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes

(2013) Hitoshi Sugihara et al.   Journal of Diabetes Investigation

Acarbose: an alternative to metformin for first-line treatment in type 2 diabetes?

(2013) Ronald CW Ma   Lancet Diabetes & Endocrinology

Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

(2013) Wenying Yang et al.   Lancet Diabetes & Endocrinology

The Evaluation of Risk Factors Associated with Adverse Drug Reactions by Metformin in Type 2 Diabetes Mellitus

(2012) Shinji Okayasu et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications

(2012) Shuji Sasaki et al.   Diabetes & Metabolism Journal

Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass

(2011) Juris J. Meier et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications

(2011) Meiling Yan et al.   CARDIOVASCULAR DRUGS AND THERAPY

β-Cell Uncoupling Protein 2 Regulates Reactive Oxygen Species Production, Which Influences Both Insulin and Glucagon Secretion

(2011) Christine A. Robson-Doucette et al.   DIABETES

Postprandial Hyperglycemia and Glycemic Variability: Should we care?

(2011) E. Standl et al.   DIABETES CARE

The role of dysregulated glucagon secretion in type 2 diabetes

(2011) D. D'Alessio   DIABETES OBESITY & METABOLISM

Effects of Acarbose on the Acceleration of Postprandial Hyperglycemia–Induced Pathological Changes Induced by Intermittent Hypoxia in Lean Mice

(2010) Masatoshi Miyamura et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Prevalence of Diabetes among Men and Women in China

(2010) Wenying Yang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin modulation of glucagon secretion: The role of insulin and other factors in the regulation of glucagon secretion

(2010) Dan Kawamori et al.   Islets

Insulin Signaling in α Cells Modulates Glucagon Secretion In Vivo

(2009) Dan Kawamori et al.   Cell Metabolism

Influence of Fat and Carbohydrate Proportions on the Metabolic Profile in Patients With Type 2 Diabetes: A Meta-Analysis

(2009) S. Kodama et al.   DIABETES CARE

Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects

(2008) Masayuki Arakawa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE